Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of travel medicine 2020-05, Vol.27 (3)
1. Verfasser:	Diaz, James H
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin Angiotensin Receptor Antagonists - adverse effects Angiotensin-Converting Enzyme 2 Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - adverse effects Betacoronavirus Coronavirus Infections - epidemiology COVID-19 Enzyme inhibitors Humans Letter to the Editor Pandemics Peptidyl-Dipeptidase A Pneumonia, Viral - epidemiology Risk Factors SARS-CoV-2 Spike Glycoprotein, Coronavirus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.
ISSN:	1195-1982 1708-8305
DOI:	10.1093/jtm/taaa041